drugset / Trial / NCT02045095
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose \[MTD\], inform the recommended phase 2 dose \[RP2D\], and identify the dose-limiting toxicities \[DLTs\]) of MLN7243.
Timeline
- Start
- 2014-01-31
- Primary completion
- 2016-11-09
- Completion
- 2016-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAK-243 | Small molecule | 1 mg | Intravenous |
| Subject | TAK-243 | Small molecule | 2 mg | Intravenous |
| Subject | TAK-243 | Small molecule | 4 mg | Intravenous |
| Subject | TAK-243 | Small molecule | 8 mg | Intravenous |
| Subject | TAK-243 | Small molecule | 12 mg | Intravenous |
| Subject | TAK-243 | Small molecule | 18 mg | Intravenous |